EUVIMEDEUVIMED entdecken
Leitlinie

DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055

Ali Afshar-Oromieh, Matthias Eiber, Wolfgang Fendler, Matthias Schmidt, Kambiz Rahbar, Hojjat Ahmadzadehfar, Lale Umutlu, Boris Hadaschik, Oliver W Hakenberg, Paolo Fornara, Jens Kurth, O Neels und 8 weitere

Nuklearmedizin - NuclearMedicine · 01.02.2023 · 62 (01) · 5-19

DOI: 10.1055/a-1984-8167 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.02.2023. Verfasst von Ali Afshar-Oromieh und 19 weiteren Autor:innen. Beteiligte Einrichtung: Universitätsklinikum Bern, Inselspital, Klinik für Nuklearmedizin, Universität Bern, Schweiz. Hauptthemen laut MEDLINE: Prostate, Prostatic Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PSMA-PET/CT for imaging prostate cancer (PC) has spread worldwide since its clinical introduction in 2011. The majority of experiences have been collected for PSMA-PET-imaging of recurrent PC. Data for primary staging of high-risk PC are highly promising. Meanwhile, a plethora of PSMA-ligands are available for clinical use (e. g. 68Ga-PSMA-11, 68Ga-PSMA-I&T, 68Ga-PSMA-617, 18F-DCFBC, 18F-DCFPyL, 18F-PSMA-1007, 18F-rhPSMA-7 and 18F-JK-PSMA-7). However, an official approval is available only for 68Ga-PSMA-11 (approved by the US FDA in 2020) and 18F-DCFPyL (approved by the US FDA in 2021). Recommendations for acquisition times vary from 1–2 h p. i. It has been shown that for the majority of tumour lesions, the contrast in PSMA-PET/CT increases with time. Therefore, additional late imaging can help to clarify unclear findings. PSMA-PET/CT should be performed prior to commencing an androgen deprivation therapy (ADT) since (long term) ADT reduces the visibility of PC lesions. Following injection of PSMA-ligands, hydration and forced diuresis are recommended for PSMA-ligands with primarily excretion via the kidneys in order to increase the visibility of tumour lesions adjacent to the urinary bladder. PSMA-ligands are physiologically taken up in multiple normal organs. For some 18F-labelled PSMA-ligands, presence of unspecific focal bone uptake has been reported. When using these tracers, focal bone uptake without CT-correlate should be interpreted with great caution. Besides prostate cancer, practically all solid tumors express PSMA in their neovasculature thereby taking up PSMA-ligands, although usually at a lower extent compared to PC. Also multiple benign lesions and inflammatory processes (e. g. lymph nodes) take up PSMA-ligands, also usually at lower extent compared to PC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProstateProstatic NeoplasmsMaleHumansPositron Emission Tomography Computed TomographyLigandsAndrogen AntagonistsNeoplasm Recurrence, LocalGallium RadioisotopesGallium Isotopes

Substanzen

LigandsAndrogen AntagonistsGallium Radioisotopesgallium 68 PSMA-11Gallium Isotopes

Autor:innen und Institutionen

  • Universitätsklinikum Bern, Inselspital, Klinik für Nuklearmedizin, Universität Bern, Schweiz.
  • Technische Universität München, Klinik für Nuklearmedizin.
  • Universitätsklinikum Essen, Klinik für Nuklearmedizin.
  • Universitätsklinikum Köln, Klinik und Poliklinik für Nuklearmedizin.
  • Universitätsklinikum Münster, Klinik für Nuklearmedizin.
  • Klinikum Westfalen, Klinik für Nuklearmedizin.

Zitieren

APA

Afshar-Oromieh, A., Eiber, M., Fendler, W., Schmidt, M., Rahbar, K., Ahmadzadehfar, H., Umutlu, L., Hadaschik, B., Hakenberg, O. W., Fornara, P., Kurth, J., Neels, O., Wester, H. J., Schwaiger, M., Kopka, K., Haberkorn, U., Herrmann, K., Krause, B. J., Deutsche Gesellschaft für Urologie e. V. (DGU), & Deutsche Röntgengesellschaft e. V. (DRG) (2023). DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055. Nuklearmedizin - NuclearMedicine, 62(01), 5-19. https://doi.org/10.1055/a-1984-8167

Vancouver

Afshar-Oromieh A, Eiber M, Fendler W, Schmidt M, Rahbar K, Ahmadzadehfar H, et al. DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055. Nuklearmedizin - NuclearMedicine. 2023;62(01):5-19. doi:10.1055/a-1984-8167

BibTeX
@article{AfsharOromieh2023,
  author = {Afshar-Oromieh, Ali and Eiber, Matthias and Fendler, Wolfgang and Schmidt, Matthias and Rahbar, Kambiz and Ahmadzadehfar, Hojjat and Umutlu, Lale and Hadaschik, Boris and Hakenberg, Oliver W and Fornara, Paolo and Kurth, Jens and Neels, O and Wester, Hans-Jürgen and Schwaiger, Markus and Kopka, Klaus and Haberkorn, Uwe and Herrmann, Ken and Krause, Bernd J and Deutsche Gesellschaft für Urologie e. V. (DGU), Deutsche Gesellschaft für Urologie e. V. (DGU) and Deutsche Röntgengesellschaft e. V. (DRG), Deutsche Röntgengesellschaft e. V. (DRG)},
  title = {DGN-Handlungsempfehlung (S1-Leitlinie) – PSMA-Liganden-PET/CT in der Diagnostik des Prostatakarzinoms – Stand: 01/2022 – AWMF-Registernummer: 031-055},
  journal = {Nuklearmedizin - NuclearMedicine},
  year = {2023},
  volume = {62},
  number = {01},
  pages = {5--19},
  doi = {10.1055/a-1984-8167}
}
Kostenlos starten →